
Ask a doctor about a prescription for Kalii hloridum 0,15% + Glucosum 5% Kabi
Potassium Chloride 0.15% + Glucose 5% Kabi, (1.5 mg + 50 mg)/ml, Solution for Infusion
Potassium Chloride + Glucose
Potassium Chloride 0.15% + Glucose 5% Kabi is a solution for infusion containing potassium chloride and glucose.
Potassium chloride is a chemical compound (a type of salt) that occurs naturally in the blood. Glucose is
one of the sources of energy for the body. This solution for infusion provides 200 kilocalories per liter.
This medicine is used as a source of carbohydrates (sugars) in the prevention and treatment of:
This medicine has a higher concentration than blood (hypertonic solution). The doctor will take this into account when determining the dose for the patient.
Before starting treatment with Potassium Chloride 0.15% + Glucose 5% Kabi, you should tell your doctor or nurse:
The doctor will closely monitor the patient's condition during treatment with this medicine. The doctor will take blood and urine samples to determine the patient's condition. Patients with heart or kidney disease should be monitored closely.
The doctor will consider whether the patient is receiving intravenous nutrition (nutrition administered through a drip into a vein).
In the case of prolonged administration of Potassium Chloride 0.15% + Glucose 5% Kabi, the patient may require additional nutrition.
Potassium Chloride 0.15% + Glucose 5% Kabi contains sugar (glucose), which may cause high blood sugar levels (hyperglycemia). In this case, the doctor may:
This is especially important in patients with diabetes.
Patients should be closely monitored. In cases where proper regulation of water content in the blood is disrupted due to increased secretion of antidiuretic hormone (ADH), infusion of fluids with low salt concentration (hypotonic solutions) may lead to low sodium levels in the blood (hyponatremia). This can cause headache, nausea, seizures, lethargy, coma, brain swelling, and death, so the occurrence of these symptoms (severe symptomatic encephalopathy with hyponatremia) is considered a life-threatening condition.
Potassium Chloride 0.15% + Glucose 5% Kabi should be administered with caution in children.
Newborns, especially premature and low-birth-weight infants, are more susceptible to low or high blood sugar levels(hypo- or hyperglycemia) during intravenous administration of glucose solutions.
Tell your doctor or nurse about all medicines you are taking, or have recently taken, and any medicines you plan to take. It is especially important to inform your doctor if you are taking:
Do not administer Potassium Chloride 0.15% + Glucose 5% Kabi through the same needle as a blood transfusion. This may cause red blood cells to break down or clump together.
Ask your doctor about using Potassium Chloride 0.15% + Glucose 5% Kabi with food and drink.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor or nurse for advice before using this medicine.
This medicine may be used in pregnant and breastfeeding women. The doctor will closely monitor the dose given to the patient. The doctor will order blood tests to monitor the levels of substances in the blood, as changes in potassium levels can affect the mother's and fetus's heart function.
Special caution is required when administering this medicine to pregnant women during labor, especially in combination with oxytocin (a hormone used to induce labor and prevent bleeding), due to the risk of hyponatremia.
This medicine does not affect the ability to drive or use machines.
This medicine is administered by a doctor or nurse.
The doctor will determine the dose and method of administration based on the patient's age, weight, clinical and biological condition, hydration status, and reason for treatment. The dose of the medicine also depends on other medicines the patient is taking.
The doctor will monitor the patient's fluid balance, blood acidity, urine flow, and electrolyte levels (especially sodium) in the blood (mainly in patients with high levels of vasopressin or patients taking other medicines that enhance the action of vasopressin), at the start of infusion and during its administration.
The doctor will determine the infusion rate.
If the patient requires a large volume or rapid infusion, the doctor will check the ECG (heart function test).
During treatment with Potassium Chloride 0.15% + Glucose 5% Kabi, the doctor will order blood tests to monitor the levels of:
If too much of the medicine is administered (in the infusion), the following may occur:
If you have any further questions about using this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency of side effects is not known.
If you experience any side effects, including those not listed in the package leaflet, you should tell your doctor or nurse. Side effects can be reported directly to the Department of Medicinal Product Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
email: [email protected]
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
There are no special storage instructions for this medicine.
Do not use this medicine after the expiry date stated on the bottle. The expiry date refers to the last day of the month.
Do not use this medicine if the solution is not clear or if particles are visible. Do not use this medicine if the bottle is damaged.
Potassium Chloride 0.15% + Glucose 5% Kabi is a clear solution, free from visible particles.
It is available in 500 ml or 1000 ml LDPE (KabiPac) bottles with a polyisoprene stopper and a polyolefin cap.
Package size: 10 bottles in a cardboard box.
Not all package sizes may be marketed.
Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw
Labesfal – Laboratórios Almiro, S.A.
Zona Industrial do Lagedo
For more information, contact the marketing authorization holder:
Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw
tel.: +48 22 345 67 89
Belgium
Potassium Chloride 0.15% + Glucose 5% Fresenius Kabi
Bulgaria
Калиев хлорид + Глюкоза Каби 1,5 mg/ml + 50 mg/ml инфузионен разтвор
Estonia
Potassium Chloride/Glucose Fresenius 1,5 mg/50 mg/ml
France
Chlorure de potassium 0,15% et glucose 5% Kabi, solution pour perfusion
Spain
Cloruro de potasio Kabi 20 mEq/l en Glucosa 5% solución para perfusion EFG
Netherlands
Kaliichloride 0.15% + Glucose 5% Fresenius Kabi
Ireland
Potassium Chloride 0.15% w/v & Glucose 5% w/v Solution for Infusion
Lithuania
Potassium Chloride/ Glucose Fresenius 1,5 mg/50 mg/ml infuzinis tirpalas
Latvia
Potassium Chloride/Glucose Fresenius 1,5 mg/50 mg/ml šķīdums infūzijām
Poland
Kalii chloridum 0,15% + Glucosum 5% Kabi
Portugal
Cloreto de Potássio 0,15% p/v e Glucose 5% p/v Kabi
Slovenia
Kalijev klorid/Glukoza Kabi 1,5 mg/50 mg v 1 ml raztopina za infundiranje
United Kingdom
Potassium Chloride 0.15% w/v & Glucose 5% w/v Solution for Infusion
Date of last revision of the package leaflet:29.06.2018
------------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
This medicine is for single use only. Any unused solution should be discarded.
Only use a clear solution, free from visible particles and with an intact package.
Route of administration
Intravenous administration using sterile equipment free from pyrogens.
Intravenous administration of potassium should be done into a large peripheral vein or central vein, to reduce the risk of vein hardening. When administering into a central vein, ensure that the catheter is not in the atrium or ventricle of the heart, to avoid local hyperkalemia.
Solutions containing potassium should be administered slowly.
Infusion rate
To avoid the risk of dangerous hyperkalemia, the infusion rate during potassium administration should not exceed 15 to 20 mmol/hour.
Do not exceed the recommended dose (see section "Dosage").
Do not add medicines with known incompatibility.
From a microbiological point of view, this medicine mixed with other medicines should be used immediately, unless mixing is performed in controlled and validated aseptic conditions. If the medicine is not used immediately, the user is responsible for the storage time and conditions of the prepared solution.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Kalii hloridum 0,15% + Glucosum 5% Kabi – subject to medical assessment and local rules.